Type 2 & other diabetes

Efficacy and safety of iGlarLixi versus IDegAsp in people with type 2 diabetes inadequately controlled with basal insulin: A systematic literature review and network meta‐analysis of non‐Asian studies

Diabetes Obes MetabPublished Systematic review and network meta-analysis of randomised controlled trials

Pooled result · HbA1c reductionResult — go to the resultMD −0.39 %-units 95% CrI −0.58 to −0.21

Authors' conclusion

Once-daily iGlarLixi was associated with superior blood glucose control and body weight benefit compared with IDegAsp in insulin-experienced populations with T2D in non-Asian RCTs.

Study context

Population
People with T2D previously treated with basal insulin who switched to iGlarLixi or IDegAsp, non-Asian randomized controlled trials (RCTs)
Participants
2,535 people4 RCTs
Comparison
iGlarLixi vs IDegAsp
  • iGlarLixin = 810
  • IDegAspn = 454reference
Outcome
HbA1c reduction
Methodological detailsnon-Asian studies, Searched Embase, MEDLINE and CENTRAL on 10 October 2023
  • non-Asian studies
  • Searched Embase, MEDLINE and CENTRAL on 10 October 2023

Pooled result

As reported in the abstract

MD

−0.39 %-units

95% CrI −0.58 to −0.21

iGlarLixivs IDegAsp
MD −0.39 %-units (95% CrI −0.58 to −0.21)

Further pooled results

OutcomeRisk ratio (95% CrI)
HbA1c <7.0%CrI1.42 (1.18–1.71)
OutcomeMD (mmol/L) (95% CrI)
Postprandial glucose reductionGreater reduction with iGlarLixi · CrI−1.38 (−2.15 to −0.63)
OutcomeMD (kg) (95% CrI)
Body weightBenefit favoured iGlarLixi · CrI−1.54 (−2.26 to −0.84)

Safety

Hypoglycaemia evaluation was inconclusive due to definitional differences between trials

Original publication

Efficacy and safety of iGlarLixi versus IDegAsp in people with type 2 diabetes inadequately controlled with basal insulin: A systematic literature review and network meta‐analysis of non‐Asian studies. Diabetes Obes Metab. Published 2 April 2025. doi:10.1111/dom.16360

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.